Previous 10 | Next 10 |
Gainers: Oasis Midstream Partners (NASDAQ: OMP ) +79% . More news on: Oasis Midstream Partners LP, Aurora Cannabis Inc., Marine Petroleum Trust, Stocks on the move, , Read more ...
BERWYN, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced today an interview with CEO Maria Maccecchini, ...
BERWYN, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced today that the protocol for its Pha...
Thinly traded nano cap Annovis Bio (NYSEMKT: ANVS ) jumps 14% premarket on light volume in reaction to data from animal models of Alzheimer's (AD) and Parkinson's (PD) diseases that, it says, demonstrated efficacy of lead candidate ANVS401 . More news on: Annovis Bio, Health...
BERWYN, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, published data from its two double-blind, placebo controlled...
Gainers: Comstock Holding Companies (NASDAQ: CHCI ) +111% . More news on: Comstock Holding Companies, Inc., ShiftPixy, Inc., Applied DNA Sciences, Inc., Stocks on the move, , Read more ...
BERWYN, Pa., April 13, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced today its CEO Maria Maccecchini, Ph.D. will s...
NEW YORK, NY / ACCESSWIRE / March 19, 2020 / Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative diseases, is scheduled to present at the Spring Investor Summit on March 25 at 3:30 p.m. EST. Due to on...
BERWYN, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s (AD) , Parkinson’s (PD) and other neurodegenerative diseases, was awarded a $1.7 million grant from the National Institutes of H...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...